<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289599</url>
  </required_header>
  <id_info>
    <org_study_id>E2307-J081-001</org_study_id>
    <nct_id>NCT02289599</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a single-center, single dose, randomized, double-blind, placebo-controlled
      study in healthy Japanese male subjects. The study will consist of 2 parts: Part A (young
      subjects) and Part B (elderly subjects). In Part A sequential cohorts of subjects will be
      treated with single ascending doses of E2307. The maximum tolerated dose (MTD) will be
      determined in Part A. Part B will be initiated after Part A is completed. In Part B one
      cohort of healthy elderly subjects will be treated with a single dose of E2307 at one dose
      level below the MTD. In part A, a total of 56 subjects will be enrolled into 7 cohorts
      sequentially and randomized 3:1 to receive either E2307 (1 mg, 3 mg, 10 mg, 30 mg, 100 mg,
      200 mg, or 300 mg) or placebo. In part B, a total of 8 subjects will be randomized, 6
      subjects to a single dose of E2307 and 2 subjects to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events/serious adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) of E2307: Cmax (maximum observed concentration)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: tmax (time at which the highest drug concentration occurs)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: AUC(0-t) [area under the concentration (AUC)-time curve from zero time to time of last quantifiable concentration]</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: AUC(0-inf) [area under the concentration-time curve from zero time extrapolated to infinite time]</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: t1/2 (terminal elimination phase half-life)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: CL/F (apparent total clearance following oral administration)</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>CL/F are calculated for E2307 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: Vz/F (apparent volume of distribution at terminal phase)</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>Vz/F are calculated for E2307 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK of E2307: AUC ratio (AUC ratio of metabolite to parent)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK of E2307: Ae (cumulative amount of drug excreted in urine up to 264 hours postdose)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine PK of E2307: CLR (renal clearance)</measure>
    <time_frame>Up to 12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference in change of mean blood pressure (BP) between E2307 and placebo</measure>
    <time_frame>24 hours predose and continue until 24 hours postdose (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT interval assessment using Holter monitoring</measure>
    <time_frame>24 hours predose through Day 2 (at 24 hours postdose)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Part A: 1 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 3 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 10 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 30 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 100 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 200 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: 300 mg E2307 (young cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Elderly cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose level below MTD from Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2307</intervention_name>
    <arm_group_label>Part A: 1 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 3 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 10 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 30 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 100 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 200 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 300 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part B: Elderly cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2307 Matching Placebo</intervention_name>
    <arm_group_label>Part A: 1 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 3 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 10 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 30 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 100 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 200 mg E2307 (young cohort)</arm_group_label>
    <arm_group_label>Part A: 300 mg E2307 (young cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parts A and B

          1. Provide written informed consent

          2. Willing and able to comply with all aspects of the protocol

             Part A: Young cohort

          3. Non-smoking, male subjects age &gt;=20 years and less than 55 years old at the time of
             informed consent

             Part B: Elderly Cohort

          4. Non-smoking, male subjects age &gt;=65 years and less than 85 years old at the time of
             informed consent

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from this study:

          1. Clinically significant illness that requires medical treatment within 8 weeks or a
             clinically significant infection that requires medical treatment within 4 weeks of
             dosing

          2. Any history of abdominal surgery that may affect PK profiles of E2307 (eg.
             hepatectomy, nephrectomy, digestive organ resection)

          3. Known history of clinically significant drug allergy (at Screening)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Japanese Subjects</keyword>
  <keyword>E2307</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

